Jan-Eric Ahlfors CEO and CSO of Fortuna Fix Presented at Unite to Cure

Jan-Eric Ahlfors, CEO and CSO of Fortuna, presented at the Fourth International Vatican Conference “Unite to Cure”. Fortuna’s directly reprogrammed cell technology platform was in a session entitled “The Pharmacy of the Future – Stem Cells and Cardiovascular, Pulmonary and Neurodegenerative Diseases”.

Fortuna is a private regenerative medicine company with a patented direct cell reprogramming technology platform (drNPC™) and a proprietary bio-scaffolding technology (RMx™), for the treatment of neurodegenerative diseases and neurotrauma. The company has its lead programs in Spinal Cord Injury and Parkinson’s disease and on-going development efforts in Stroke, Traumatic Brain Injury, Hearing Loss and ALS. The company has developed a proprietary, large-scale and fully automated manufacturing system for production of autologous drNPCs. As a company, we have prioritized fully automated manufacturing for production of our personalized directly reprogrammed neural precursor cells (“drNPCs”) as we recognize manufacturing as a significant hurdle most companies face in large-scale manufacturing of cellular therapies.

With its fully automated manufacturing system, Fortuna aims to be the first to manufacture and bring to the clinic personalized neural precursor cells for treatment of diseases in the fields of neurodegeneration and neurotrauma. Manufacturing of autologous drNPCs is accomplished with a rapid, high throughput, and fully automated process, which does not involve engineering, animal components, or staged pluripotency. Patients suffering from neurotrauma or neurodegeneration will be able to get treatment with their own neural cells providing functional integration without immunosuppression or ethical issues (the technology uses no fetal, embryonic-like, or other ethically challenging processes).

“Fortuna’s mission is to “Cure CNS diseases with next-generation ethical regenerative medicine solutions” and we are honored to be part of this extraordinary event with a goal synergistic to our efforts”, said Jan-Eric Ahlfors, CEO and CSO of Fortuna. For more information, please visit http://fortunafix.com.

This entry was posted in Chronic Spinal Cord Injury Research, Regenerative Medicine, Spinal Research, Stem Cell Research and tagged , . Bookmark the permalink.